Revelation Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
REVB Nasdaq 8731 https://www.revbiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Revelation Biosciences Inc

Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Sep 24th, 2024 10:00 am
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Aug 21st, 2024 9:30 pm
REVB: Bolsters Cash Amid Positive Trial Results - Aug 12th, 2024 1:07 pm
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 - Aug 9th, 2024 8:15 pm
REVB Releases Positive Test Results—Potential Catalyst - Jul 8th, 2024 10:27 am
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday? - Jun 24th, 2024 4:06 pm
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity - Jun 24th, 2024 1:00 pm
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini - Jun 13th, 2024 1:21 pm
REVB: In Great Position For Testing - May 13th, 2024 12:10 pm
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 - May 10th, 2024 8:52 pm
REVB Begins Trials with Good Cash on Hand - Mar 25th, 2024 11:06 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 - Mar 22nd, 2024 8:15 pm
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) - Mar 13th, 2024 1:00 pm
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference - Mar 12th, 2024 1:00 pm
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini - Mar 4th, 2024 2:00 pm
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) - Feb 13th, 2024 2:00 pm
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering - Feb 5th, 2024 9:41 pm
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering - Feb 1st, 2024 11:00 am
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) - Jan 30th, 2024 2:00 pm
REVB Continues March to Trials - Jan 26th, 2024 11:18 am